How to Outsource Peptide Scale-Up Manufacturing

Scaling peptide synthesis from milligrams in the lab to kilograms for clinical supply is one of the most challenging steps in drug development. Many companies outsource this process to contract development and manufacturing organizations (CDMOs) that have the equipment, expertise, and regulatory infrastructure to handle it.

This guide explains how to navigate the scale-up outsourcing process successfully.

Why Scale-Up Is Challenging

Peptide synthesis does not scale linearly. A process that works well at 1 gram may fail at 100 grams. The challenges include:

Heat management: Coupling reactions generate heat. At large scale, this heat can cause side reactions and reduce yield. Reactors must be designed with adequate cooling.

Mixing efficiency: Ensuring uniform mixing of resin and reagents is easy in a small flask but difficult in a large reactor. Poor mixing leads to incomplete coupling and lower purity.

Reagent consumption: The economics of reagent use change at scale. Expensive coupling reagents that are fine at lab scale may make production-scale synthesis cost-prohibitive.

Purification: Crude peptide at large scale requires large HPLC columns and significant solvent volumes. Purification often becomes the rate-limiting step.

Waste management: Peptide synthesis generates substantial waste, especially TFA-containing solutions. Large-scale waste handling requires specialized infrastructure.

The cost of goods for a peptide drug decreases by approximately 60% to 70% when moving from lab scale to optimized production scale. However, reaching that optimized state requires significant investment in process development.

When to Start Planning for Scale-Up

Start planning for scale-up much earlier than most companies realize.

Milestone	Action
Lead candidate selection	Begin CDMO evaluation
Preclinical studies	Select CDMO, negotiate contract
IND-enabling studies	Technology transfer, process development
IND filing	GMP production of clinical supply

A common mistake is waiting until after IND filing to start scale-up. By then, you have lost 12 to 18 months and may face supply delays for your clinical trial.

A single GMP batch of a 30-residue peptide at kilogram scale can consume over 10,000 liters of solvent, making waste handling infrastructure one of the most overlooked cost drivers in scale-up outsourcing.

Choosing a CDMO

The CDMO you choose will be a critical partner for years. Take the time to evaluate options thoroughly.

Key Evaluation Criteria

Criteria	What to Assess
Peptide Experience	Number of peptide products manufactured, scale achieved
Regulatory Track Record	FDA inspection history, number of products filed
Equipment	Synthesizer capacity, HPLC purification scale, lyophilization
Capacity	Available slots, lead times, ability to scale further
Quality Systems	cGMP compliance, change control, CAPA program
Technical Team	PhD scientists with scale-up experience
Financial Stability	Long-term viability, diversified client base
Location	Logistics, time zone compatibility, regulatory jurisdiction

Questions to Ask During CDMO Evaluation

• What is the largest peptide batch you have produced?
• How many peptide APIs have you manufactured under GMP?
• What is your current lead time for new peptide projects?
• Can you handle peptides with non-standard amino acids or modifications?
• What analytical capabilities do you have in-house?
• How do you handle process deviations and out-of-specification results?

Site Visits

Always visit your shortlisted CDMOs before making a decision. During the visit, evaluate:

• Cleanliness and organization of manufacturing areas
• Equipment condition and maintenance records
• Staff competence and engagement
• Quality culture (are SOPs followed, are deviations reported)
• Communication style and responsiveness

Technology Transfer

Technology transfer is the process of moving your peptide synthesis process from your lab to the CDMO's facility. It is the most critical phase of the outsourcing relationship.

What to Transfer

Provide the CDMO with comprehensive documentation:

• Detailed synthesis protocol (every step, every parameter)
• Analytical methods with validation data
• Raw material specifications and approved suppliers
• In-process control methods and acceptance criteria
• Historical batch data and development reports
• Known challenges and troubleshooting notes

Technology Transfer Steps

1. Documentation package preparation (4 to 8 weeks)
2. CDMO review and gap analysis (2 to 4 weeks)
3. Method transfer and verification (4 to 8 weeks)
4. Process development runs (4 to 12 weeks)
5. GMP demonstration batch (2 to 4 weeks)
6. Process validation (6 to 12 weeks for 3 batches)

Common Technology Transfer Problems

• Incomplete documentation from the sponsor
• Differences in equipment between sponsor and CDMO
• Reagent or resin lot-to-lot variability
• Scale-dependent effects not observed at lab scale
• Analytical method reproducibility issues

Address these issues proactively by maintaining clear communication and involving your scientists in the transfer process.

Before signing a CDMO contract, request batch records from at least two comparable peptide programs they have scaled. Review their crude purity data at each scale to confirm they can handle the specific coupling and purification challenges your sequence presents.

Process Development at Scale

The CDMO will need to optimize your process for their equipment and scale. This is normal and expected.

Areas of Optimization

Coupling conditions: Reaction time, temperature, and reagent equivalents may need adjustment at scale. The CDMO's process development team will run experiments to find optimal conditions.

Resin handling: Loading, swelling, and washing procedures change at scale. Larger reactors have different flow characteristics that affect these steps.

Purification: The CDMO will develop a purification strategy using their HPLC systems. Column size, flow rate, gradient profile, and fraction collection criteria all need optimization.

Lyophilization: If your product is lyophilized, the CDMO will develop a cycle appropriate for their equipment. This may require thermal analysis and cycle optimization runs.

Cost Structure

Scale-up manufacturing costs have several components.

One-Time Costs

Component	Cost Range
Technology transfer	$50,000 to $150,000
Process development	$100,000 to $300,000
Method validation (analytical)	$30,000 to $80,000
Process validation (3 batches)	$200,000 to $600,000
Regulatory support	$20,000 to $50,000

Per-Batch Manufacturing Costs

Batch Size	Approximate Cost per Batch
100 g crude	$50,000 to $100,000
500 g crude	$100,000 to $250,000
1 kg crude	$200,000 to $500,000
5 kg crude	$500,000 to $1,500,000
10+ kg crude	$1,000,000+

Per-batch costs decrease on a per-gram basis as scale increases. The cost reduction is driven by better reagent utilization, lower labor cost per gram, and improved process efficiency.

Quality and Regulatory Considerations

GMP manufacturing of peptide APIs requires robust quality oversight.

Quality Agreement

Establish a quality agreement with your CDMO that covers:

• Roles and responsibilities for quality decisions
• Change control notification requirements
• Deviation investigation and reporting procedures
• Complaint handling
• Audit rights and frequency
• Annual product quality review
• Stability testing responsibilities

Release Testing

Every batch must undergo release testing before it can be used in clinical trials or distributed commercially. Standard release tests include:

• Identity (amino acid analysis, mass spectrometry)
• Purity (HPLC, capillary electrophoresis)
• Related substances (peptide impurities)
• Residual solvents (GC)
• Water content (Karl Fischer)
• Endotoxin (LAL test)
• Microbial testing

Regulatory Filing Support

Your CDMO should support your regulatory filings by providing:

• Process descriptions for the chemistry, manufacturing, and controls (CMC) section
• Batch analysis data
• Process validation reports
• Stability data
• Facility information (including FDA registration numbers)

Begin CDMO evaluation at lead candidate selection, not after IND filing, because a 12 to 18 month technology transfer timeline can delay your clinical supply if you start too late.

FAQ

How long does it take to scale up a peptide from lab to GMP production?

Plan for 12 to 18 months from starting the CDMO relationship to having GMP material available. This includes technology transfer (3 to 6 months), process development (2 to 4 months), and process validation (3 to 6 months). Complex peptides with difficult sequences may take longer.

Can I switch CDMOs after starting scale-up?

Yes, but it is expensive and time-consuming. You essentially restart the technology transfer process with the new CDMO. Budget 6 to 12 additional months and $200,000 to $500,000 for the transition. Avoid this by choosing your CDMO carefully from the start.

What is the minimum batch size for GMP peptide manufacturing?

Most CDMOs have minimum batch sizes of 50 to 100 grams of crude peptide. Some specialize in smaller batches for early clinical trials. The economics improve at larger scales, so discuss your projected needs over multiple years with potential CDMOs.

Should I use the same CDMO for both API manufacturing and drug product?

Using one CDMO for both simplifies supply chain management and reduces technology transfer requirements. However, not all peptide API manufacturers have drug product capabilities. Evaluate whether integrated services or best-in-class specialists are the right strategy for your program.

How do I protect my intellectual property when outsourcing to a CDMO?

Sign comprehensive confidentiality and IP agreements before sharing any technical information. Limit access to your process details to essential CDMO personnel. Include IP ownership clauses in your manufacturing agreement that clearly state that all process improvements belong to you.